Clinical Trials · NCT04259801
First Research Study to Look at How Two Medicines, NNC0480-0389 and Semaglutide, Work Together in Healthy People, in People With High Body Weight and in People With Diabetes
- Phase
- Phase 1
- Recruitment status
- Completed
- Sponsor
- Novo Nordisk A/S
- Enrollment
- 152
- Start date
- Feb 2020
- Locations
- 1 site, Netherlands
- Primary endpoint
- Number of treatment emergent adverse events (TEAE) in Part 1